Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VRAX Stock Forecast 2025-2026
$0.49
Current Price
$3.20M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VRAX Price Targets
+513.5%
To High Target of $3.00
+513.5%
To Median Target of $3.00
+513.5%
To Low Target of $3.00
VRAX Price Momentum
-23.4%
1 Week Change
+4.3%
1 Month Change
-71.2%
1 Year Change
-78.2%
Year-to-Date Change
-84.7%
From 52W High of $3.20
+39.7%
From 52W Low of $0.35
📊 TOP ANALYST CALLS
Did VRAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Virax Biolabs is one of their latest high-conviction picks.
Latest VRAX Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, VRAX has a bullish consensus with a median price target of $3.00 (ranging from $3.00 to $3.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.49, the median forecast implies a 513.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 513.5% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 513.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRAX Analyst Ratings
1
Buy
0
Hold
0
Sell
VRAX Price Target Range
Low
$3.00
Average
$3.00
High
$3.00
Current: $0.49
Latest VRAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $3.00 |
Virax Biolabs Group Ltd. (VRAX) Competitors
The following stocks are similar to Virax Biolabs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VRAX
Virax Biolabs
mkt cap
4.12M
Virax Biolabs Group Ltd. (VRAX) Financial Data
Virax Biolabs Group Ltd. has a market capitalization of $3.20M with a P/E ratio of -0.3x. The company generates $2,986 in trailing twelve-month revenue with a -838.2% profit margin.
Revenue growth is -67.5% quarter-over-quarter, while maintaining an operating margin of -160,788.3% and return on equity of -83.8%.
Valuation Metrics
Market Cap
$3.20M
Enterprise Value
$-68,145
P/E Ratio
-0.3x
PEG Ratio
-0.3x
Price/Sales
1,071.6x
Growth & Margins
Revenue Growth (YoY)
-67.5%
Gross Margin
N/A
Operating Margin
-160,788.3%
Net Margin
-838.2%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+107.4%
Current Ratio
11.4x
Debt/Equity
10.6x
ROE
-83.8%
ROA
-48.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Virax Biolabs Group Ltd. (VRAX) Business Model
About Virax Biolabs Group Ltd.
What They Do
Develops diagnostic testing kits for viral diseases.
Business Model
Virax Biolabs generates revenue through the development and distribution of diagnostic testing kits aimed at detecting viral diseases. Their products cater to a broad range of clients including healthcare institutions, government health departments, and research organizations, ensuring a steady demand for their offerings.
Additional Information
The company's innovations are particularly relevant during global health crises, providing essential tools for public health surveillance and response. By focusing on advancing medical diagnostics, Virax Biolabs contributes significantly to community health and the efficacy of healthcare systems in managing viral threats.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
19
CEO
Mr. James Foster
Country
United Kingdom
IPO Year
2022
Website
viraxbiolabs.comVirax Biolabs Group Ltd. (VRAX) Latest News & Analysis
Latest News
Quick Summary
Virax Biolabs (NASDAQ: VRAX) is advancing its diagnostic technology for post-acute infection syndromes, positioning itself for significant data releases in 2026 after recent clinical milestones.
Why It Matters
Virax Biolabs' advancements in diagnostic technology for Long COVID could lead to significant market demand, impacting revenue potential and stock performance in 2026.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs Group Limited announced a private placement of 12.5 million ordinary shares at $0.40 each, along with options for the same amount, exercisable for five years.
Why It Matters
Virax Biolabs is raising capital through a private placement, potentially diluting shares but providing funds for growth. The exercise of options could further impact share value and liquidity.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs secured $5 million in a private placement, extending its cash runway into H1 2028. This supports ongoing regulatory studies for COVID-related conditions and platform expansion.
Why It Matters
Virax Biolabs' extended cash runway until mid-2028 supports ongoing studies and regulatory submissions, enhancing its potential for growth and partnership opportunities in the evolving biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs has completed patient recruitment for a UK clinical study on its ViraxImmune™ assay for detecting T cell dysfunction in Post-Acute Infection Syndromes, including Long COVID, ahead of schedule.
Why It Matters
Successful recruitment for the ViraxImmune™ assay study indicates strong potential for diagnostic advancements in Long COVID and related syndromes, potentially boosting Virax's market position and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs (NASDAQ: VRAX) has signed a Research Services Agreement with Emory University to conduct clinical studies on its ViraxImmune™ product focusing on immune profiling in long COVID patients.
Why It Matters
Virax's partnership with Emory University for clinical studies on long COVID may enhance its product credibility and market potential, affecting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
4 months ago
Quick Summary
Virax Biolabs Group Limited appointed Iain Miller, PhD, as an Independent Director, effective July 29, 2025, replacing Yair Erez, who is resigning for other commitments.
Why It Matters
The appointment of Dr. Iain Miller as an Independent Director may signal strategic shifts at Virax, potentially impacting governance and future direction, affecting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VRAX Stock
What is Virax Biolabs Group Ltd.'s (VRAX) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Virax Biolabs Group Ltd. (VRAX) has a median price target of $3.00. The highest price target is $3.00 and the lowest is $3.00.
Is VRAX stock a good investment in 2026?
According to current analyst ratings, VRAX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRAX stock?
Wall Street analysts predict VRAX stock could reach $3.00 in the next 12 months. This represents a 513.5% increase from the current price of $0.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Virax Biolabs Group Ltd.'s business model?
Virax Biolabs generates revenue through the development and distribution of diagnostic testing kits aimed at detecting viral diseases. Their products cater to a broad range of clients including healthcare institutions, government health departments, and research organizations, ensuring a steady demand for their offerings.
What is the highest forecasted price for VRAX Virax Biolabs Group Ltd.?
The highest price target for VRAX is $3.00 from Yi Chen at HC Wainwright & Co., which represents a 513.5% increase from the current price of $0.49.
What is the lowest forecasted price for VRAX Virax Biolabs Group Ltd.?
The lowest price target for VRAX is $3.00 from Yi Chen at HC Wainwright & Co., which represents a 513.5% increase from the current price of $0.49.
What is the overall VRAX consensus from analysts for Virax Biolabs Group Ltd.?
The overall analyst consensus for VRAX is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are VRAX stock price projections?
Stock price projections, including those for Virax Biolabs Group Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 4:53 AM UTC